Trial Profile
A Phase I, randomized, open-label, active-controlled, three-way treatment trial assessing pharmacokinetics, bioavailability and safety of three doses of CAM2038 q1w (once-weekly) (buprenorphine FluidCrystal injection depot), versus active comparators, intravenous and sublingual buprenorphine, in healthy volunteers under naltrexone blockage
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary) ; Buprenorphine (Primary) ; Buprenorphine (Primary) ; Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Pharmacokinetics
- Sponsors Camurus
- 21 Oct 2016 According to Braeburn Pharmaceuticals media release, new data will be presented at a joint annual meeting of the International Society of Addiction Medicine (ISAM) and the Canadian Society of Addiction Medicine (CSAM) in Oct 2016.
- 28 May 2014 New trial record